Sangamo is on the steering commitee for the Forum HIV Cure Project (with Merck, Bristol-Meyers Squib, and Gilead Sciences)
.
THE FORUM HIV CURE PROJECT - June 17, 2014
Objectives: To facilitate discussions between US government agencies, industry, academia, and community on the topic of clinical trials and regulatory issues pertaining to HIV cure research
To discuss or reach consensus on acceptable clinical trial risk of potential cure treatments
To discuss appropriate trial designs for cure-related research:
- Potential assays to be used for trial endpoints
- Logistics/parameters of treatment interruptions, or valid alternatives, in trials assessing potential cure treatment outcomes
- Assessment of functional cures if complete eradication is not possible
- Appropriate trial populations for the different potential interventions
To discuss or reach consensus on ethics and informed consent appropriate for cure-related researc
Status:
The project has recently launched, with the public meeting planned for June 17, 2014
The Steering Committee for this project includes:
Co-Chairs:
Daniel Kuritzkes, MD Harvard Medical School; Brigham & Women’s Hospital
Veronica Miller, PhD Forum for Collaborative HIV Research
National Institutes of Health:
Carl Dieffenbach, PhD DAIDS/NIAID
Robert Eisinger, PhD Office of AIDS Research/NIH
Food and Drug Administration:
Celia Witten, PhD, MD Center for Biologics Evaluation & Research
Carol Weiss, MD, PhD Center for Biologics Evaluation & Research
Jeffrey Murray, MD, MPH Center for Drug Evaluation & Research
Community:
David Evans Project Inform
Mark Harrington Treatment Action Group
Rowena Johnston, PhD American Foundation for AIDS Research
Industry:
Romas Geleziunas, PhD Gilead Sciences, Inc
George Hanna, MD Bristol-Myers Squibb
Daria Hazuda, PhD Merck Research Laboratories
Winson Tang, MD, FACP Sangamo Biosciences, Inc
|
